Risk factors for peak dose dyskinesia in 100 levodopa-treated Parkinsonian patients

Canadian Journal of Neurological Sciences

Volumn 23, Issue 3, 1996, Pages 189-193

  Blanchet, Pierre J ^a   Allard, Pierre ^a   Grégoire, Laurent ^a   Tardif, François ^a   Bédard, Paul J ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029748579     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710003849X     Document Type: Article

References (34)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-379.
2. Nutt JG. Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 1990; 40: 340-345.
3. Crossman AR, Clarke CE, Boyee S, Robertson RG, Sambrook MA. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 1987; 14: 428-435.
4. Bédard PJ, Gomez-Mancilla B, Blanchette P, et al. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992; 19: 134-137.
5. Filion M, Tremblay L, Bédard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991; 547: 152-161.
6. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: implications for the neural mechanisms that mediate dopamine agonists-induced dyskinesia. Brain 1992; 115: 809-824.
7. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990; 5: 100-108.
8. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonisms and the complications of long-term levodopa therapy. Neurology 1979; 29: 1253-1260.
9. Pederzoli M, Girotti F, Scigliano G, et al. L-Dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology 1983; 33: 1518-1522.
10. Friedman A. Levodopa-induced dyskinesia: clinical observations. J Neurol 1985; 232: 29-31.
11. Tanner CM, Kinori I, Goetz CG, et al. Age at onset and clinical outcome in idiopathic Parkinson's disease. Neurology 1985; 35 (Suppl. I): 276.
12. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2: 73-91.
13. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991; 41: 622-629.
14. Wu RM, Chiu HC, Wang M, Chen RC. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease. J Neural Transm [P-D Sect] 1993; 5: 127-133.
15. Diamond SG, Markham CH, Hoehn MM, et al. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989; 39: 1187-1190.
16. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990; 53: 224-226.
17. Lang AE, Meadows JC, Parkes JD, Marsden CD. Early onset of the "on-off ' phenomenon in children with symptomatic parkinsonism. J Neurol Neurosurg Psychiatry 1982; 45: 823-825.
18. Langston JW, Ballard P. Parkinsonism induced by l-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 1984; 11 (Suppl.): 160-165.
19. Bergmann KJ, Mendoza MR, Yahr MD. Parkinson's disease and long-term levodopa therapy. In: Yahr MD, Bergmann KJ, eds. Advances in Neurology. Vol 45: Parkinson's disease. New York: Raven Press, 1986: 463-467.
20. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988; 38: 1410-1416.
21. Hoehn MMM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand 1985; 71: 97-106.
22. Farm S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11 (Suppl.): 200-206.
23. Klawans HL, Crossett P, Dana N. Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of L-Dopa-induced dyskinesias. In: Calne DB, Chase TN, Barbeau A, eds. Advances in Neurology, Vol. 9. New York: Raven Press, 1975: 105-112.
24. Sweet, RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Ann Intern Med 1975; 83: 456-463.
25. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991-996.
26. Poewe WH, Lees AJ, Stern GM. Low-dose L-Dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36: 1528-1530.
27. Tanner CM. Drug-induced movement disorders (tardive dyskinesia and dopa-induced dyskinesia). In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology, Vol 5(49): Extrapyramidal Disorders. Amsterdam: Elsevier Science, 1986: 185-204.
28. Lawless JF. Statistical Models and Methods for Lifetime Data. New York: J Wiley & Sons, Eds. 1982.
29. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-1038.
30. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-Dopa-treated parkinsonian patients. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in Neurology, Vol 60: Parkinson's disease: from Basic Research to Treatment. New York: Raven Press, 1993: 698-702.
31. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11: 200-206.
32. Rajput AH, Uitti RJ. When to use levodopa in parkinsonism. Lancet 1986; 1(8493): 1324-1325.
33. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989; 34: 193-196.
34. Wilson JA, Smith RG. The prevalence and aetiology of long-term L-Dopa side-effects in elderly parkinsonian patients. Age and Ageing 1989; 18: 11-16.